ARDELYX, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
34175 ARDENWOOD BLVD., FREMONT, CA, 94555
Mailing Address
34175 ARDENWOOD BLVD., FREMONT, CA, 94555
Phone
510-745-7047
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$39.14M
Net Income
$334.65M
Total Liabilities
$173.29M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- Achieved significant 75% revenue growth in 2023, reaching $125 million, primarily driven by strong product sales.
- Successfully launched XPHOZAH after FDA approval in October 2023, generating $15 million in initial sales.
Insider Trading
BUY
9 insiders
28 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.